Nadia Yousaf
Overview
Explore the profile of Nadia Yousaf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1565
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hindocha S, Hunter B, Linton-Reid K, George Charlton T, Chen M, Logan A, et al.
Radiother Oncol
. 2024 Apr;
195:110266.
PMID: 38582181
Background: Pneumonitis is a well-described, potentially disabling, or fatal adverse effect associated with both immune checkpoint inhibitors (ICI) and thoracic radiotherapy. Accurate differentiation between checkpoint inhibitor pneumonitis (CIP) radiation pneumonitis...
2.
Harvey C, Nahar K, McKeown J, Lo S, Farag S, Yousaf N, et al.
J Immunother Cancer
. 2024 Jan;
12(1).
PMID: 38296594
Background: Immune checkpoint inhibitor (ICI) gastrointestinal toxicity (gastritis, enteritis, colitis) is a major cause of morbidity and treatment-related death. Guidelines agree steroid-refractory cases warrant infliximab, however best management of infliximab-refractory...
3.
Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer
Wu M, Shepherd S, Fendler A, Carr E, Au L, Harvey R, et al.
Cancer Cell
. 2023 Apr;
41(5):821-823.
PMID: 37116490
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
4.
Ng K, Boumelha J, Enfield K, Almagro J, Cha H, Pich O, et al.
Nature
. 2023 Apr;
616(7957):563-573.
PMID: 37046094
B cells are frequently found in the margins of solid tumours as organized follicles in ectopic lymphoid organs called tertiary lymphoid structures (TLS). Although TLS have been found to correlate...
5.
Andres M, Ramalingam S, Rosen S, Baksi J, Khattar R, Kirichenko Y, et al.
Cardiooncology
. 2022 Nov;
8(1):21.
PMID: 36424659
Background: The full range of cardiovascular complications related to the use of Immune checkpoint inhibitors (ICI) is not fully understood. We aim to describe the spectrum of cardiovascular adverse events...
6.
Fendler A, Shepherd S, Au L, Wu M, Harvey R, Wilkinson K, et al.
Cell Rep Med
. 2022 Oct;
3(10):100781.
PMID: 36240755
Patients with blood cancer continue to have a greater risk of inadequate immune responses following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the context of the...
7.
OSullivan H, dArienzo P, Yousaf N, Cui W, Popat S
Eur J Cancer
. 2022 Aug;
174:318-320.
PMID: 35948502
No abstract available.
8.
9.
Cui W, Milner-Watts C, OSullivan H, Lyons H, Minchom A, Bhosle J, et al.
Eur J Cancer
. 2022 Jun;
171:44-54.
PMID: 35704974
Background: Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation sequencing (NGS) is standard but tissue quantity, quality, and time-to-results remains problematic....
10.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Schmitt A, et al.
Cancer Cell
. 2022 Apr;
40(4):438.
PMID: 35413273
No abstract available.